Constant Therapeutics
May 23, 2021
Constant Therapeutics is a small, private, and clinical stage therapeutics company developing Mas receptor agonists for the treatment of COVID-19, CNS disorders, rare diseases, and other indications. It’s lead compound, TXA127, is a pharmaceutical formulation of the natural human peptide Angiotensin-(1-7) (Ang-(1-7)). Lead clinical programs include COVID-19, chronic stroke recovery, epidermolysis bullosa and cardiomyopathy associated with Duchenne Muscular Dystrophy.
Recent News
- Canyon Labs Launches Expanded Reprocessing Validation Services for Medical Devices
- Connecting with Life Sciences in Logan
- Halia Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
- Ratio Therapeutics Enters into Research Collaboration, License Agreement with RayzeBio to Advance a Novel Radiopharmaceutical Program
- Co-Diagnostics Completes New Vector Smart® Laboratory Installations Amid Rising Dengue Activity in Florida
- Co-Diagnostics Launches Integrated Cloud and Mobile Infrastructure in India
